Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

727 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody responses in Crohn's disease.
Vermeire S, Rutgeerts P. Vermeire S, et al. Among authors: rutgeerts p. Gastroenterology. 2004 Feb;126(2):601-4. doi: 10.1053/j.gastro.2003.12.020. Gastroenterology. 2004. PMID: 14762797 Review. No abstract available.
Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction.
Vandewalle-El Khoury P, Colombel JF, Joossens S, Standaert-Vitse A, Collot M, Halfvarson J, Ayadi A, Landers CJ, Vermeire S, Rutgeerts P, Targan SR, Chamaillard M, Mallet JM, Sendid B, Poulain D. Vandewalle-El Khoury P, et al. Among authors: rutgeerts p. Am J Gastroenterol. 2008 Apr;103(4):949-57. doi: 10.1111/j.1572-0241.2007.01648.x. Epub 2007 Nov 28. Am J Gastroenterol. 2008. PMID: 18047546
Candida albicans colonization and ASCA in familial Crohn's disease.
Standaert-Vitse A, Sendid B, Joossens M, François N, Vandewalle-El Khoury P, Branche J, Van Kruiningen H, Jouault T, Rutgeerts P, Gower-Rousseau C, Libersa C, Neut C, Broly F, Chamaillard M, Vermeire S, Poulain D, Colombel JF. Standaert-Vitse A, et al. Among authors: rutgeerts p. Am J Gastroenterol. 2009 Jul;104(7):1745-53. doi: 10.1038/ajg.2009.225. Epub 2009 May 26. Am J Gastroenterol. 2009. PMID: 19471251
NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. Vermeire S, et al. Among authors: rutgeerts p. Gastroenterology. 2002 Jul;123(1):106-11. doi: 10.1053/gast.2002.34172. Gastroenterology. 2002. PMID: 12105838 Free article.
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Among authors: rutgeerts p. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256 Free article.
727 results